Newron Pharmaceuticals SpA - Company Profile
Powered by
All the data and insights you need on Newron Pharmaceuticals SpA in one report.
- Save hours of research time and resources with
our up-to-date Newron Pharmaceuticals SpA Strategy Report
- Understand Newron Pharmaceuticals SpA position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Newron Pharmaceuticals SpA (Newron Pharmaceuticals) is a research-based biopharmaceutical company that focuses on the discovery, development, and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company’s marketed the product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newton's other products in the pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. It operates along with its subsidiaries in the UK, Switzerland, Sweden, and the US. Newron is headquartered in Bresso, Milan, Italy.
Newron Pharmaceuticals SpA premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Marketed Product: | Xadago |
Xadago (Safinamide) - Parkinson’s Disease | |
Pipeline | |
XYZ | |
XYZ | |
XYZ |
Competitor Comparison
Key Parameters | Newron Pharmaceuticals SpA | Pharming Group NV | Nanobiotix SA | Biofrontera AG | Silence Therapeutics Plc |
---|---|---|---|---|---|
Headquarters | Italy | Netherlands | France | Germany | United Kingdom |
City | Bresso | Leiden | Paris | Leverkusen | London |
State/Province | - | - | Ile-de-France | Nordrhein-Westfalen | England |
No. of Employees | 23 | 415 | 102 | 91 | 116 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Ulrich Kostlin | Chairman | Executive Board | 2013 | - |
Stefan Weber | Director; Chief Executive Officer | Executive Board | 2012 | - |
Ravi Anand | Chief Medical Officer | Senior Management | 2005 | - |
Roberto Galli | Vice President - Finance | Senior Management | 2012 | - |
Dennis Dionne | Vice President - Commercial Affairs | Senior Management | 2017 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer